Now Available: Spotlight on Stilla Technologies Remi Dangla, PhD – CEO. Click here to read.
Proteomics firm Alamar Biosciences is preparing its NULISA (NUcleic acid-Linked Immuno-Sandwich Assay) platform for an early-access release later this year and a broad commercial launch in 2024. The NULISA system is based on the proximity ligation assay (PLA) originally commercialized by Olink Bioscience, the forerunner of Olink. PLA uses pairs of antibodies attached to unique DNA sequences to...
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, announced completion of its $60.75M Series A financing round.
Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced it has raised $80 million in a Series B financing. The round was led by Novalis LifeSciences and included new investors Illumina Ventures, Albany Capital and Catalio Capital Management, among others. They joined Northpond Ventures, Good Ventures, and other existing inve...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors (including Illumina Ventures). The funds will be used to advance the company’s ...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
